Toutes les études
RecrutementPHASE1, PHASE2INTERVENTIONNEL

A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)

This research is looking into a new gene therapy called AVB-101 for a specific type of dementia called Frontotemporal Dementia with Progranulin Mutations (FTD-GRN). This condition affects younger people and leads to problems with a brain protein called progranulin. The study wants to find out if AVB-101 is safe, can restore this protein to normal levels, and potentially slow down the disease. All participants will receive a one-off treatment delivered directly to the brain, and doctors will monitor them for five years. The study involves people aged 30 to 75 who have FTD-GRN and meet specific health requirements.

En un coup d'œil

Statut
Recrutement
Phase
PHASE1, PHASE2
Sponsor
AviadoBio Ltd
Objectif d'inscription
18
Démarrer
30 août 2023
Achèvement estimé
21 Mar 2030

De quoi parle cette étude ?

This study is looking into a new treatment for a specific type of dementia called Frontotemporal Dementia with Progranulin Mutations, or FTD-GRN. FTD is a brain condition that gets worse over time and can affect a person's behaviour, speech, and movement.

In FTD-GRN, these problems happen because there isn't enough of a vital protein called progranulin in the brain. This lack of protein causes brain cells to die, which then affects how the brain works. The new treatment, called AVB-101, is a type of 'gene therapy'. This means it's designed to help the body make more of the missing progranulin protein.

The main goals of this study are to: 1) check if AVB-101 is safe for people with FTD-GRN, 2) see if it can bring progranulin levels back to normal in the brain, and 3) explore if it can help slow down or even stop the disease from getting worse. This is an early-stage study, meaning it's one of the first times this treatment is being tested in people.

Points clés

  • This study is for people with a specific type of Frontotemporal Dementia called FTD-GRN.
  • It's testing a new gene therapy, AVB-101, to see if it's safe and can help raise progranulin levels.
  • Participants will receive a one-time treatment delivered directly into the brain.
  • The study lasts for five years after the treatment.
  • There's no placebo; everyone gets the active treatment.
  • It's an early-stage study, so the full effects and risks are still being learned.

Qui peut être éligible ?

The study is looking for both men and women between the ages of 30 and 75. To be considered, you must have been diagnosed with Frontotemporal Dementia due to a specific genetic change (a GRN mutation).

Doctors will also check how your dementia is affecting you, looking for certain signs related to changes in behaviour or language. You must also be able to follow all the study instructions and attend appointments, and you'll need to have a chosen study partner who can help support you and provide information during the study.

There are also some reasons why you might not be able to join. For example, if your dementia is very severe, or if you have other health conditions that could affect your brain or make the treatment unsafe. You also can't have had certain other experimental treatments or gene therapies before.

Cet étude pourrait-elle vous convenir ?

Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.

  1. Are you between 30 and 75 years old?
  2. Have you been diagnosed with Frontotemporal Dementia caused by a GRN gene mutation?
  3. Are you able and willing to attend all study visits and follow instructions?
  4. Do you have a family member or friend who can be your 'study partner'?
  5. Do you have any other serious health conditions that might prevent you from joining?
  6. Have you had any other gene therapy or similar experimental treatments before?
Répondez à chaque question pour voir votre résultat.

En quoi consiste la participation ?

If you join this study, you won't receive a 'dummy' treatment; everyone will receive the actual study treatment, AVB-101. This treatment is given just once, directly into the brain through a procedure. After this single treatment, doctors will closely monitor your health and how you're responding for a period of five years. This will involve regular check-ups, tests, and assessments to see how you are doing.

Risques et avantages potentiels

Participating in research studies like this can have potential benefits, such as gaining access to a new, experimental treatment that might help with your condition, and contributing to medical knowledge benefiting others. However, there are also potential risks involved, including those related to the procedure to deliver the treatment, and possible side effects from AVB-101 itself, which are not yet fully known. It's very important to remember that you have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Emplacements (19)

  • The Ohio State University (OSU) Wexner Medical Center
    Code postal vérifié
    Columbus, États-Unis· Recrutement
  • Vanderbilt University Medical Centre
    Code postal vérifié
    Nashville, United States· Recrutement
  • Houston Methodist Hospital
    Code postal vérifié
    Houston, États-Unis· Recrutement
  • UZ Leuven
    Code postal vérifié
    Leuven, Belgium· Recrutement
  • Centre des sciences de la santé Sunnybrook
    Code postal vérifié
    Toronto, Canada· Recrutement
  • Fondazione IRCCS Istituto Neurologico Carlo Besta
    Code postal vérifié
    Milan, Italie· Recrutement
  • Amsterdam UMC
    Code postal vérifié
    Amsterdam, Netherlands· Recrutement
  • NEURO-CARE Sp. z o.o. Sp. Komandytowa
    Code postal vérifié
    Katowice, Poland· Recrutement
  • Neurologia Slaska Centrum Medyczne
    Code postal vérifié
    Katowice, Poland· Recrutement
  • Uniwersyteckie Centrum Kliniczne, SUM w Katowicach
    Code postal vérifié
    Katowice, Poland· Recrutement
  • Euromedis Sp. z o.o.
    Code postal vérifié
    Szczecin, Poland· Recrutement
  • Centrum Medyczne NeuroProtect Sp z o.o.
    Code postal vérifié
    Warsaw, Poland· Recrutement

Questions fréquentes

What is FTD-GRN?

FTD-GRN is a type of Frontotemporal Dementia caused by a change in a specific gene, leading to low levels of a protein called progranulin in the brain.

What is gene therapy?

Gene therapy is a new kind of treatment that aims to correct problems with genes to help the body work correctly, in this case, by hopefully increasing progranulin protein levels.

Is AVB-101 a cure for FTD-GRN?

AVB-101 is an experimental treatment being studied to see if it can help treat FTD-GRN, but it is not yet known if it can cure the condition.

Will I get a placebo in this study?

No, there is no placebo in this study. All participants will receive the active study treatment, AVB-101.

Combien de temps serai-je impliqué dans l'étude ?

After receiving the one-time treatment, you will be monitored by the study team for five years.

Comment en savoir plus

AviadoBio Clinical Trials

Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.

Intéressé à participer ?

Inscrivez votre intérêt

Partagez vos coordonnées et l'équipe de recherche pour "A Study to Evaluate the Safety and Effect of AVB-101, a Gene… vous contactera si vous êtes éligible. Consultez toujours votre médecin avant d'accepter de participer.

Discussion

Discussion communautaire

Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.